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Summary The present study was undertaken to examine whether the presence of primary lung cancer could
affect the antitumour activities of pleural cavity macrophages (PCM) and peripheral blood monocytes (PBM).
PCM by pleural lavage and PBM were simultaneously obtained from 14 lung cancer patients not showing
invasion of the pleural cavity. PCM and PBM were isolated by percoll gradient centrifugation and adherence.
The lavage method yielded about 16.8 +9.6 (s.e.) x 106 cells, which consisted of 80.7% PCM, 17.6%
lymphocytes and 1.6% other cells. The cytotoxic activities of PCM and PBM against allogeneic melanoma
(A375) cells were assessed by a 72h 125I-IUdR release assay. The lavaged PCM showed spontaneously high
tumour cytotoxic activity which was dependent on the effector/target ratio. In 13 out of 14 cancer patients,
PCM were significantly more cytotoxic to melanoma cells than PBM. In contrast, there were no significant
differences in production of tumour necrosis factor (TNF-a) or interleukin (IL-l) between PCM and PBM.
When the abilities of PCM and PBM of the same patient to produce these monokines were compared, PCM
produced much more TNF-cx than PBM, thus indicating a correlation between the expression of spontaneous
macrophage-mediated cytotoxicity and spontaneous TNF-a production by PCM. These results suggest that
PCM may play an important role in host defence against invasion of the pleural cavity by cancer cells.
It is well accepted that activated macrophages are important
in host defence against primary and/or metastatic cancer in
murine systems (Fidler, 1985; Sone, 1986). Human
monocytes (Kleinerman et al., 1983; Sone et al., 1984) and
alveolar macrophages (Lemarbre et al., 1980; Sone & Fidler,
1981) with or without activation stimuli are known to be
cytotoxic to tumorigenic cells. Activated monocyte-
macrophages are known to produce various monokines, such
as interleukin 1 (IL-1) (Dinarello, 1984) and tumour necrosis
factor (TNF) (Bharat et al., 1985), which are responsible for
antitumour immune responses. Macrophage infiltration has
been seen in human tumours (Gauci, 1976), and a close
relationship has been found between the extent of
macrophage infiltration and incidence of metastases of
human breast tumours (Lauder et al., 1977).
In several murine tumour systems, the presence of
progressively growing tumours has been shown to be
accompanied by several changes in macrophage function,
such as an increased number of blood monocytes (Rhodes,
1977), increased expression of monocyte Fc receptors
(Rhodes, 1977) and suppression of migration or the
chemotactic response of macrophages in the peritoneal cavity
or at the tumour growth site (Snyderman et al., 1978;
Meltzer & Stevenson, 1977, 1978; Pasternack et al., 1987). In
contrast, macrophages of animals bearing growing tumours
are shown to express tumoricidal activity in response to
appropriate activation stimuli (Meltzer & Stevenson, 1978;
Sone & Fidler, 1981). Similarly, some (Meltzer & Stevenson,
1977; Sone & Fidler, 1981) but not all (Gudewicz & Saba,
1977) reports have shown that the phagocytic abilities of
macrophages remain intact even in the presence of tumours.
Most of these findings regarding antitumour functions of
macrophages come from murine studies.
The pleural cavity is the virtual space between the visceral
and the parietal pleura and it is surrounded by mesothelial
membrane. Malignant pleural effusions are frequently seen in
association with malignancies of the lung (Hausheer &
Yarbro, 1985). Two-thirds of pleural tumours are metastases
from primary lung cancers. Although metastatic spread of
cancer cells to the pleura and/or pleural cavity might be
influenced by both tumour cell properties and host factors,
the functional integrity of PCM may be important in the
destruction of tumour cells reaching the pleura and/or
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pleural cavity. Little is known, however, about the role of
PCM in the defence against cancer. Accordingly, in the
present study we examined the effect of the presence of
primary lung cancer on the natural antitumour functions of
PCM. We also compared the tumoricidal activity and
monokine (TNF-a and IL-1) producing abilities of PCM
with those of PBM.
Materials and methods
Cell cultures
A375 cells, derived from a human melanoma, were adapted
to growth in culture (Sone & Tsubura, 1982; Sone et al.,
1984). All cultures were maintained on plastic in RPMI 1640
supplemented with 10% heat-inactivated fetal bovine serum
(FBS; Whittaker M.A. Bioproducts Inc., Walkersville, MD,
USA) and gentamicin, designated CRPMI 1640, at 37°C in a
humidified atmosphere of 5% CO2 in air. Cytotoxicity
assays were performed when the cultured target cells were in
the exponential growth phase. All reagents were free of
endotoxin as determined by the Limulus amoebocyte lysate
test (sensitivity limit, 0.1 ngml1).
Patients
Fourteen patients with resectable primary lung cancer not
associated with malignant pleural effusion were included in
this study. None of the patients had received any anticancer
therapy. The clinical characteristics of the patients are
summarised in Table I. Histological classification established
that there were 10 squamous cell carcinomas, two small cell
carcinomas and two adenocarcinomas. The tumour-nodes-
metastasis classification system (Union Internationale Contre
la Cancer, 1987) was used for staging of the disease. Seven
patients were classified as stage I, three as stage II and four
as stage III. The degree of pleural invasion by the lung
cancer was classified as grade 0, no visceral pleural invasion;
grade 1, pleural invasion limited to within the visceral
pleura; and grade 2, pleural invasion extending beyond the
visceral pleura to the neighbouring lobe or chest wall
(Nagashima et al., 1987).
Isolation and culture of PCM and PBM
After properly obtaining informed consent, pleural lavage
was performed as follows. Immediately after thoracotomy,
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the pleural cavity was irrigated with 1,000ml of 0.9% NaCI
solution (saline) prewarmed to 37°C. The saline was
collected aseptically in heparinised (10Uml-1) vacuum
bottles and centrifuged at 1,200r.p.m. (400g) for 15min to
obtain cell pellets. The cell pellets were resuspended in 15ml
of phosphate buffered saline (PBS). To obtain PBM, 20ml
of peripheral blood was simultaneoulsy obtained from each
patient with a heparinised syringe during the operation.
Mononuclear cells containing PCM or PBM were separated
from the peripheral blood or from lavaged cells, respectively,
by discontinuous gradient centrifugation using a lymphocyte
separation medium (Litton Bionetics, Kensington, MD,
USA). Then PCM-rich or PBM-rich cells were isolated from
the mononuclear cells by discontinuous gradient
centrifugation in 46% percoll solution at 1,800r.p.m. (600g)
for 30min. Next, the PCM-rich and PBM-rich cell
suspensions were washed twice with RPMI 1640. More than
80% of the cells were PCM or PBM, as judged from their
morphology and by staining with non-specific esterase (Table
I). Some 105 PCM or PBM were plated into each well of a
Microtest III plate with 96 wells (Falcon Plastics Co.) and
incubated for 2h at 37°C. The PCM or PBM monolayers
were then washed twice with CRPMI 1640 to remove all
non-adherent cells. At this point, the purity of the monocyte-
macrophages was >99% as judged by their morphology and
non-specific esterase staining.
Cytotoxicity by PCM or PBM
Cytotoxicity was assayed by measuring the release of radio-
activity as described in detail previously (Sone et al., 1986;
Ustugi & Sone, 1986). A375 melanoma target cells in the
exponential growth phase were incubated for 24h in CRPMI
1640 with 0.4pCiml- 1 '251-iododeoxyuridine (specific
activity 5Cimg-1; Amersham International, Little Chalfont,
UK). A375 melanoma cells were previously found to be
susceptible to the cytotoxicity expressed by IL-1 and TNF-a
(Okubo et al., 1989). Unless otherwise described, 104 target
cells were then plated into wells containing PCM or PBM,
and 16h later they were washed to remove non-adherent and
dead cells and re-fed with fresh CRPMI 1640. After further
incubation for 56h, the cultures were washed twice with
PBS; adherent, presumably viable, target cells were lysed
with 0.1 ml of 0.1 N NaOH and their radioactivity was
measured in a gamma-counter.
The percentage cytotoxicity mediated by human PCM or
PBM was calculated as follows:
A-B
% cytotoxicity= 100 x A
where A represents the c.p.m. in cultures of target cells and
B represents the c.p.m. in cultures of target cells and PCM
or PBM.
Assay of IL-1 activity
Extracellular IL-1-rich supernatants were obtained from
cultures of PCM or PBM incubated in medium alone for
24h at a concentration of 105 cells. The IL-1 activity
contained in the supernatants was measured as described
previously (Tandon et al., 1986). Thymocytes obtained from
C3H/HeJ mice of 4-6 weeks old (The Jackson Laboratories,
Bar Harbor, ME, USA) were suspended in CRPMI 1640 at
concentration of 1.5 x 106ml-1 and incubated with or
without 10% macrophage supernatants in the presence of a
suboptimal dose (2plml-1) of PHA-P (Difco Laboratories,
Detroit, MI, USA). As a positive control, thymocytes plus
PHA-P were incubated in medium containing 5Umml- of
recombinant IL-I1 (Nishida et al., 1987). The cultures were
incubated for 72h at 37°C in 5% CO2 in air. Eighteen hours
before the end of the incubation, thymocyte proliferation
was assessed by labeling with 25pCiml-1 of 3H-thymidine
(6.7Cimmol-1; Amersham, Arlington Heights, IL, USA).
Upon completion of the incubation, the cells were harvested
on a glass fibre in a cell harvester, MASH II, and cellular
3H-thymidine incorporation was assessed with a scintillation
counter. The IL-1 activity in the macrophage supernatants
was expressed as the stimulation index (SI), which was
calculated from the 3H-TdR uptake (c.p.m.) of thymocytes
plus PHA-P with the test supernatant/3H-TdR uptake
(c.p.m.) of thymocytes plus PHA-P incubated in medium
alone, without any test supernatant.
Assay of TNF activity
The TNF activity contained in the supernatant obtained
from cultures of PCM or PBM was measured by a method
described previously (Collotta et al., 1984). In brief, 3 x 104
mouse L-929 fibroblast cells treated with 1 pgmlP-1 of
actinomycin D were added to the wells of a 96-well
Microtest III plate, and incubated in medium containing
50% of the supernatant to be tested for TNF activity. After
18h the supernatants were removed and the adherent cells
were washed and stained with a 0.5% solution of crystal
violet in methanol/water (1:4,v/v). The end point on the
microtitre plate was determined with an automatic Titertek
Multiscan autoreader set for absorption at 540 nm.
Preliminary experiments showed that, under the experimental
conditions described here, there was a linear correlation
between the degree of dye uptake by target cells and the
number of adherent cells (data not shown). Percent
cytotoxicity was calculated by the formula.
C-T
% cytotoxicity= 100 x C
where C is the absorbance of the control and T is that of the
treated sample. The cells exposed to culture medium alone
were set at 0% lysis, while those exposed to 3M guanidine
hydrochloride solution provided an end point for 100% lysis.
Statistical analysis
The statistical significance of differences between test groups
was analysed by Student's t test.
Results
Yields of PCM and PBM
The lavage and isolation methods used here yielded about
16.8+9.6 (s.e.) x 106 cells per patient (Table I). These cells
consisted of 80.7+3.3% macrophages, 17.6+3.5% lympho-
cytes and 1.6+0.6% others. The total number of PBM
recovered by this method was 4.8+ 1.0 x 106 cells, which
consisted of 82.0% +1.9% monocytes, 17.1 +2.0% lympho-
cytes and 0.8+0.3% other cells (Table I).
Spontaneous tumoricidal activities of PCM and PBM
Next, we investigated whether the PCM obtained by lavage
from these lung cancer patients without malignant pleural
effusion were able to kill tumour cells without further
stimulation (Table II). Various numbers of PCM were plated
for 2h in CRPMI 1640 at 37°C and then washed thoroughly
to remove non-adherent cells. These adherent PCM at the
indicated concentrations were then incubated with 1 x 104
allogeneic A375 melanoma cells prelabelled with 12sI
iododeoxyuridine. At the same time, the spontaneous
cytotoxic activities of the PBM were examined at various
E/T ratios. The initial ratio of PCM or PBM to tumour cells
in the different test groups ranged from 10:1 to 1: 1. As
shown in Table II, an increase in the number of PCM or
PBM per well was associated with enhancement of their
natural cytotoxicity. Moreover, the spontaneous tumoricidal
activity of PCM was significantly higher than that of PBM
at all the examined ratios of effector to target cells.
Next, we compared the natural cytotoxic activities of PBM
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Table I Profiles of examined lung cancer patients
Grade No. of lavaged Differential count (%)
Patient no. Age Sex Cell type (stage) cells (x 106) PCM Lymphocytes Others
1 59 M Small cell 0 (II) 0.7 80 17 3
2 68 M Smail cell 0 (11) 0.6 85 15 0 3 58 M Adenocarcinoma cell 0 (I) 1.3 95 4 1
4 63 M Adenocarcinoma cell 1 (II) 0.3 74 26 0
5 73 M Squamous cell 0 (I) 1.5 86 13 1
6 61 M Squamous cell 0 (I) 2.0 84 15 1
7 67 M Squamous cell 0 (I) 1.2 96 4 0
8 51 M Squamous cell 0 (I) 0.7 86 11 3 9 73 M Squamous cell 0 (I) 80.0 84 8 8
10 45 M Squamous cell 0 (III) 2.3 73 26 1
11 66 M Squamous cell 1 (I) 1.6 81 16 3 12 69 M Squamous cell 1 (III) 24.0 70 28 2 13 59 M Squamous cell 1 (III) 117.0 90 10 0
14 59 M Squamous cell 1 (III) 1.8 46 54 0
Mean+s.e. 16.8+9.6 80.7+3.3 17.6+3.5 1.6+0.6
Table II Spontaneous cytotoxicity by PCM or PBM from lung
cancer patients without malignant effusion
% cytotoxicity against A375 cells'
EIT ratio PCM PBM
10:1 54.4+5.lbc 24.0+8.1
5:1 43.8+5.6c 17.6+6.7
1:1 17.8+5.5d 9.1 +4.0
aPCM and PBM obtained simultaneously from eight patients with
primary lung cancer were incubated for 72h with 1 x 104 labelled
A375 melanoma cells. % cytotoxicity was determined as compared to
tumour cells alone; bMean+s.e. of nine patients; cSignificantly
different from that of PBM at the corresponding E/T ratio (P<0.01);
dSignificantly different from that of PBM at the corresponding E/T
ratio (P<0.05).
PBM or PCM were incubated for 72h with 1 x 104 labelled
A375 melanoma cells. Again, the data shown in Figure 1
demonstrate that the PCM of all 14 patients showed
significantly higher natural cytotoxicity than their PBM.
Ability of PCM and PBM to produce monokines
We recently found that activated human blood monocytes
can produce IL-I and TNF-a (Tandon et al., 1986; Okubo et
al., 1989). To examine whether the PCM and PBM were able
to produce spontaneously monokines (TNF-a and IL-1) into
culture supernatants, 105 PCM or PBM were incubated for
24h in CRPMI 1640, and then the supernatants were
harvested. In the first experiment, two dilutions of the
supernatants from PCM or PBM were tested for TNF-a.
TNF-c production by PCM was relatively higher, although
not significantly, compared to the PBM (Table III). In a
parallel experiment, the IL-1 activities of the supernatants
were also measured. Recombinant IL-lf (5Uml-1)
significantly stimulated thymocyte proliferation in the
presence of PHA-P (11.8 times) as compared to the control
cultures. Under the same experimental conditions, there was
no significant difference in production of IL-1 between PCM
and PBM obtained from six of the patients (3.3 + 1.6 versus
3.2+ 1.1). Next, we compared the abilities of PBM and PCM
from the same patient to produce IL-I and TNF-a. For this,
the relative index for both TNF-a and IL-l was calculated as
follows: value for PCM/value for PBM. As shown in Figure
2, the PCM and PBM of the same patient produced the
same levels of IL-1 in all six patients, whereas TNF-a
production by PCM was significantly higher than that of
PBM in four of these patients.
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Figure 1 Tumoricidal potential of PCM and PBM against
allogeneic A375 cells. PCM or PBM were simultaneously
harvested from the same patient, and then incubated with A375
melanoma cells at an effector/target ratio of 10:1. The assays
were terminated 72h later. Bars show mean+s.e. of 14 lung
cancer patients.
Discussion
Our present studies demonstrate that the PCM of lung
cancer patients without malignant pleural effusion were
spontaneously highly cytotoxic to IL-1 and TNF-a sensitive
allogeneic melanoma (A375) cells and that PCM had
significantly greater ability than PBM to produce TNF-a.
Monocyte functions such as chemotactic responsiveness
(Snyderman et al., 1978) and release of IL-1 in response to
endotoxin (Pollack et al., 1983; Yokota et al., 1987) were
found to be defective in cancer patients. Moreover, many
(Cameron & Stromberg, 1984; Kleinerman et al., 1983;
Mantovani et al., 1980; Peri et al., 1981) but not all (Fidler
et al., 1986) studies have shown that the antitumour
activities of PBM in patients with malignancies were
impaired. Defects in PBM functions could be detrimental to
host survival, since activated human monocytes are known
to kill cancer cells (Sone et al., 1986). Of particular interest is
our new finding that PCM of lung cancer patients without
invasion of the pleural cavity exhibited higher spontaneous
cytotoxicity than PBM (Figure 1 and Table II). Recently,
Nakahashi et al. (1984) reported that PCM of lung cancer538 S. KIMURA et al.
Table III Production of monokines by PCM or PBM from 6 lung cancer
patients
IL-1 activitya
Source 1% supernatant 10% supernatant TNF-cx activity
PCM 2.5+0.4c 3.3+0.7c 30.3+ 12.6d
PBM 2.2+0.3 3.2+0.4 19.5+ 9.1
al% or 10% of supernatants obtained from cultures of 105 PCM or PBM
were assayed for IL-1 activity by proliferation assay of C3H/HeJ mouse
thymocytes as described in Material and methods; bTNF activity in 50%
supernatant was assessed by cytotoxicity assay against actinomycin D-treated
L 929 cells; CThe stimulation index (mean+s.e.) was calculated as follows:
3H-TdR uptake by PHA-stimulated thymocytes in medium with 1% or 100%
supernatant/3H-TdR uptake by PHA-stimulated thymocytes incubated in
medium alone; dMean % cytotoxicity+s.e.
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Figure 2 Comparison of abilities of PCM and PBM to produce
IL-1 or TNF. PCM or PBM simultaneously harvested from the
same patient were incubated for 24h in medium, and then the
IL-1 activity in 10% supernatants and TNF activity in 50%
supernatants were measured, respectively, as described in
Materials and methods. Relative ratios were calculated as follows:
value for PCM/value for PBM of the same patient. Bars show
mean+ s.e. of six patients.
patients expressed spontaneous antitumour activity against
lung cancer cells, as assessed by measuring 3H-thymidine
uptake, and that the cytostatic activity of PCM from
patients with grade 1 pleural invasion was markedly high
compared with grade 0 and 3 patients. This finding was
confirmed and extended by the present study, showing that
PCM from grade 0 and grade 1 patients showed highly
spontaneous cytolytic activity against allogeneic melanoma
cells, as assessed by measuring the 125I-IUdR release.
Moreover, in the present study we showed that PCM from
these lung cancer patients spontaneously produced higher
levels of TNF-a than PBM (Figure 2). Although the
mechanisms responsible for this increase in the natural
tumour cytotoxicity of PCM are not fully understood,
spontaneous antitumour activity and TNF-a production by
PCM could antedate tumour spread and make a host more
resistant to the invasion of lung cancer cells into the pleural
cavity, since macrophages are known to be important in host
defence against primary and/or metastatic cancer (Fidler,
1985; Sone, 1986).
PCM in the pleural cavity seem to be matured and/or
differentiated originally from bone marrow precursors
through monocytes in the blood (Van Oud Alblas & Van
Furth, 1982). Together with this, the present finding that
PCM exhibited spontaneously higher cytolytic activity than
PBM suggests that PCM may be in a so-called 'stimulated
and/or activated' state to destroy cancer cells invading
beyond the pleura. Nevertheless, it is still unclear whether
the cytotoxic activity of PCM is spotaneously high before
the onset of lung cancer or becomes high as a result of the
cancer emergence.
The present finding that there was a dissociation in the
productions of IL-1 and TNF-oa between PCM and PBM
obtained simultaneously from the same lung cancer patient is
interesting. That is, there was no difference in IL-1
production between PCM and PBM, but PCM produced
higher levels of TNF-a than PBM. One possibility to explain
this difference in monokine production between PCM and
PBM is that TNF-oa and IL-1 production and secretion by
monocyte-macrophages may be regulated by differential
mechanisms. Indeed, Burchett et al. (1988) recently
demonstrated that although freshly isolated monocytes
produced TNF-a and IL-1 after LPS stimulation, cultures of
monocytes resulted in maintenance of TNF-a production,
but in marked reduction of IL-1 production by monocyte-
derived macrophages. These findings seem to be confirmed
and extended by the present observations, suggesting that the
abilities of monocyte-macrophages to secrete TNF-a and
IL-1 may vary independently with their state of differentia-
tion or maturation, tissue of origin, and exposure to
microenvironmental stimuli.
IL-1 and TNF-a are important antitumour monokines by
which human monocyte-macrophages kill tumour cells
(Feinman et al., 1987; Okubo et al., 1989; Onozaki et al.,
1985; Ziegler-Heitbrock et al., 1986). This is the case in our
system, which showed the abilities of PBM and PCM of lung
cancer patients to produce both monokines. Moreover, the
present finding of a close association of spontaneous
cytotoxicity of the PCM with TNF-a, not with IL-1
production, suggests that TNF-a may be an important
cytotoxic effector in PCM-mediated tumour cell killing. On
the other hand, IL-1 is also a monokine which magnifies a
variety of immune and inflammatory responses (Dinarello,
1984). These findings, together with the present preliminary
findings showing a difference in IL-1 production between
PCM and PBM, suggest that mature macrophages like PCM
located in the pleural cavity may play a major role in
maintenance of natural defences against the development
and/or spread of cancer without extensive activation of other
pulmonary cavity inflammation or immune effector cells.
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